Mike Romanos appointed CEO of Crescendo Biologics

Crescendo Biologics

8 February 2011

Crescendo Biologics Limited (Crescendo) today announces the appointment of Mike Romanos as Chief Executive Officer. Dr Romanos has been Chief Scientific Officer of the company since May 2009 and has led the formation of the company and the development of its proprietary antibody fragment technologies.

During this time, the company has made significant progress in the establishment of its team and its technology platforms. This has included the establishment of a colony of engineered mice completely devoid of endogenous antibody polypeptides, announced in September. The proprietary ‘triple knockout’ mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.

Dr Romanos has more than 23 years’ biotech and pharma industry experience and within the last 10 years has held senior global positions leading major parts of GlaxoSmithKline Discovery.

Clive Dix, Chairman of Crescendo said: “Today’s announcement reflects the growing maturity of Crescendo and the progress the company has made under Mike’s leadership. We have seen significant advances in the technology platform and I am sure that with Mike now taking on the CEO position Crescendo will deliver real value from its world class, proprietary technology platforms and grow to become a leader in next-generation antibody therapeutics.”

Read the full article

More Midven News

Biotectix Announces Acquisition of Assets from Chameleon BioSurfaces Ltd.

8 March 2011 Ann Arbor, Michigan – Biotectix, LLC announced today the acquisition of...

read more

Fertility company hatches success after Midven Funding

8 February 2011 A West Midlands company that has the ultimate goal of increasing...

read more
Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now